Minoxidil Topical — Competitive Intelligence Brief

Minoxidil Topical (Minoxidil Topical) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel opener. Area: Dermatology.

marketed Potassium channel opener ATP-sensitive potassium channels Dermatology Small molecule

Target snapshot

Minoxidil Topical (Minoxidil Topical) — Dr. dr. Lili Legiawati, SpKK(K). Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Minoxidil Topical TARGET	Minoxidil Topical	Dr. dr. Lili Legiawati, SpKK(K)	marketed	Potassium channel opener	ATP-sensitive potassium channels
Sevoflurane (Preconditioning)	Sevoflurane (Preconditioning)	University of Zurich	marketed	Volatile anesthetic with cardioprotective preconditioning properties	Mitochondrial ATP-sensitive potassium channels (mitoKATP); protein kinase C; endothelial nitric oxide synthase
Minoxidil 5% Topical Solution	Minoxidil 5% Topical Solution	Triple Hair Inc	marketed	Potassium channel opener	ATP-sensitive potassium channels (KATP)
Minoxidil lotion 2%	Minoxidil lotion 2%	Mae Fah Luang University Hospital	marketed	Potassium channel opener / topical hair growth stimulant	ATP-sensitive potassium channels (KATP); exact follicle-specific target unclear
Levosimendan Injection	Levosimendan Injection	Peking University Third Hospital	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
Levosimontane injection	Levosimontane injection	Qilu Hospital of Shandong University	marketed	Calcium sensitizer / inotropic agent	Cardiac troponin C; ATP-sensitive potassium channels
metformin+ gliclazide	metformin+ gliclazide	GlaxoSmithKline	marketed	Antidiabetic combination (biguanide + sulfonylurea)	Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel opener class)

1. Kissei Pharmaceutical Co., Ltd. · 2 drugs in this class
2. Astellas Pharma Inc · 1 drug in this class
3. Cardurion Pharmaceuticals, Inc. · 1 drug in this class
4. Dr. dr. Lili Legiawati, SpKK(K) · 1 drug in this class
5. Eurofarma Laboratorios S.A. · 1 drug in this class
6. GlaxoSmithKline · 1 drug in this class
7. Allergan · 1 drug in this class
8. Triple Hair Inc · 1 drug in this class